Solid Biosciences Inc. Operating Expenses
Solid Biosciences Inc. (SLDB) reported Operating Expenses of $57.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Solid Biosciences Inc. operating expenses for the quarter ending 2026-06-30 was $57.38M, a 37.63% increase year-over-year.
- Solid Biosciences Inc. operating expenses for the quarter ending 2026-03-31 was $57.31M, a 43.08% increase year-over-year.
- Solid Biosciences Inc. operating expenses for the quarter ending 2025-12-31 was $49.40M, a 23.83% increase year-over-year.
- Solid Biosciences Inc. operating expenses for the quarter ending 2025-09-30 was $48.06M, a 36.60% increase year-over-year.
- Solid Biosciences Inc. operating expenses for fiscal 2025 was $179.21M, a 38.14% increase from fiscal 2024.
- Solid Biosciences Inc. operating expenses for fiscal 2024 was $129.73M, a 24.44% increase from fiscal 2023.
- Solid Biosciences Inc. operating expenses for fiscal 2023 was $104.25M, a 8.99% decline from fiscal 2022.
- Solid Biosciences Inc. operating expenses for fiscal 2022 was $114.55M, a 33.39% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $57.38M 10-Q · filed 2026-08-06 | $114.69M 10-Q · filed 2026-08-06 | $164.09M derived: sum of 3 quarters · filed 2026-08-06 | $212.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $57.31M 10-Q · filed 2026-05-12 | $106.71M derived: sum of 2 quarters · filed 2026-05-12 | $154.77M derived: sum of 3 quarters · filed 2026-05-12 | $196.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $49.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $97.46M derived: sum of 2 quarters · filed 2026-03-19 | $139.15M derived: sum of 3 quarters · filed 2026-08-06 | $179.21M 10-K · filed 2026-03-19 |
| 2025-09-30 | $48.06M 10-Q · filed 2025-11-03 | $89.75M derived: sum of 2 quarters · filed 2026-08-06 | $129.80M 10-Q · filed 2025-11-03 | $169.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $41.69M 10-Q · filed 2026-08-06 | $81.75M 10-Q · filed 2026-08-06 | $121.64M derived: sum of 3 quarters · filed 2026-08-06 | $156.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $40.05M 10-Q · filed 2026-05-12 | $79.95M derived: sum of 2 quarters · filed 2026-05-12 | $115.13M derived: sum of 3 quarters · filed 2026-05-12 | $142.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $39.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $75.08M derived: sum of 2 quarters · filed 2026-03-19 | $102.87M derived: sum of 3 quarters · filed 2026-03-19 | $129.73M 10-K · filed 2026-03-19 |
| 2024-09-30 | $35.18M 10-Q · filed 2025-11-03 | $62.97M derived: sum of 2 quarters · filed 2025-11-03 | $89.83M 10-Q · filed 2025-11-03 | $112.10M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $27.79M 10-Q · filed 2025-08-12 | $54.65M 10-Q · filed 2025-08-12 | $76.92M derived: sum of 3 quarters · filed 2025-08-12 | $100.03M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $26.86M 10-Q · filed 2025-05-15 | $49.13M derived: sum of 2 quarters · filed 2025-05-15 | $72.24M derived: sum of 3 quarters · filed 2025-05-15 | $99.08M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $22.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $45.38M derived: sum of 2 quarters · filed 2025-03-06 | $72.22M derived: sum of 3 quarters · filed 2025-03-06 | $104.25M 10-K · filed 2025-03-06 |
| 2023-09-30 | $23.11M 10-Q · filed 2024-11-06 | $49.96M derived: sum of 2 quarters · filed 2024-11-06 | $81.99M 10-Q · filed 2024-11-06 | $116.55M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $26.84M 10-Q · filed 2024-08-13 | $58.87M 10-Q · filed 2024-08-13 | $93.44M derived: sum of 3 quarters · filed 2024-08-13 | $114.57M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $32.03M 10-Q · filed 2024-05-15 | $66.60M derived: sum of 2 quarters · filed 2024-05-15 | $87.73M derived: sum of 3 quarters · filed 2024-05-15 | $119.28M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $34.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $55.70M derived: sum of 2 quarters · filed 2024-03-13 | $87.25M derived: sum of 3 quarters · filed 2024-03-13 | $114.55M 10-K · filed 2024-03-13 |
| 2022-09-30 | $21.13M 10-Q · filed 2023-11-08 | $52.68M derived: sum of 2 quarters · filed 2023-11-08 | $79.98M 10-Q · filed 2023-11-08 | $101.79M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $31.55M 10-Q · filed 2023-08-14 | $58.85M 10-Q · filed 2023-08-14 | $80.65M derived: sum of 3 quarters · filed 2024-03-13 | $102.22M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $27.30M 10-Q · filed 2023-05-11 | $49.10M derived: sum of 2 quarters · filed 2024-03-13 | $70.67M derived: sum of 3 quarters · filed 2024-03-13 | $92.95M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $43.37M derived: sum of 2 quarters · filed 2024-03-13 | $65.65M derived: sum of 3 quarters · filed 2024-03-13 | $85.87M 10-K · filed 2024-03-13 |
| 2021-09-30 | $21.57M 10-Q · filed 2022-11-10 | $43.85M derived: sum of 2 quarters · filed 2022-11-10 | $64.07M 10-Q · filed 2022-11-10 | $85.42M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $22.28M 10-Q · filed 2022-08-11 | $42.50M 10-Q · filed 2022-08-11 | $63.85M derived: sum of 3 quarters · filed 2023-03-23 | $85.07M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $20.22M 10-Q · filed 2022-04-27 | $41.57M derived: sum of 2 quarters · filed 2023-03-23 | $62.79M derived: sum of 3 quarters · filed 2023-03-23 | $81.77M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $21.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $42.57M derived: sum of 2 quarters · filed 2023-03-23 | $61.55M derived: sum of 3 quarters · filed 2023-03-23 | $88.41M 10-K · filed 2023-03-23 |
| 2020-09-30 | $21.23M 10-Q · filed 2021-11-03 | $40.20M derived: sum of 2 quarters · filed 2021-11-03 | $67.06M 10-Q · filed 2021-11-03 | $99.39M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $18.97M 10-Q · filed 2021-08-16 | $45.83M 10-Q · filed 2021-08-16 | $78.16M derived: sum of 3 quarters · filed 2021-08-16 | $107.88M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $26.86M 10-Q · filed 2021-05-14 | $59.19M derived: sum of 2 quarters · filed 2021-05-14 | $88.91M derived: sum of 3 quarters · filed 2021-05-14 | $115.88M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $32.33M 10-K · filed 2020-03-12 | $62.05M derived: sum of 2 quarters · filed 2020-11-05 | $89.02M derived: sum of 3 quarters · filed 2020-11-05 | $119.32M 10-K · filed 2022-03-14 |
| 2019-09-30 | $29.72M 10-Q · filed 2020-11-05 | $56.69M derived: sum of 2 quarters · filed 2020-11-05 | $86.99M 10-Q · filed 2020-11-05 | $109.37M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $26.97M 10-Q · filed 2020-08-06 | $57.27M 10-Q · filed 2020-08-06 | $79.66M derived: sum of 3 quarters · filed 2020-08-06 | $98.81M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $30.30M 10-Q · filed 2020-05-07 | $52.69M derived: sum of 2 quarters · filed 2020-05-07 | $71.84M derived: sum of 3 quarters · filed 2020-05-07 | $90.02M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $22.39M 10-K · filed 2020-03-12 | $41.54M derived: sum of 2 quarters · filed 2020-03-12 | $59.71M derived: sum of 3 quarters · filed 2020-03-12 | $75.69M 10-K · filed 2021-03-15 |
| 2018-09-30 | $19.15M 10-K · filed 2020-03-12 | $37.33M derived: sum of 2 quarters · filed 2020-03-12 | $53.30M 10-Q · filed 2019-11-12 | $68.46M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $18.18M 10-K · filed 2020-03-12 | $34.15M 10-Q · filed 2019-08-14 | $49.31M derived: sum of 3 quarters · filed 2020-03-12 | $63.01M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $15.97M 10-K · filed 2020-03-12 | $31.13M derived: sum of 2 quarters · filed 2020-03-12 | $44.83M derived: sum of 3 quarters · filed 2020-03-12 | $56.72M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $15.16M 10-K · filed 2019-03-13 | $28.86M derived: sum of 2 quarters · filed 2019-03-13 | $40.74M derived: sum of 3 quarters · filed 2019-03-13 | $54.86M 10-K · filed 2020-03-12 |
| 2017-09-30 | $13.70M 10-K · filed 2019-03-13 | $25.58M derived: sum of 2 quarters · filed 2019-03-13 | $39.70M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $11.89M 10-K · filed 2019-03-13 | $26.00M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $14.11M 10-K · filed 2019-03-13 | |||
| 2016-12-31 | $25.58M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |